- Home
- ISPC vs MYNZ Comparison
ISPC vs MYNZ Comparison
Compare ISPC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPC | MYNZ |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 5.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ISPC | MYNZ |
|---|---|---|
| Price | $0.25 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 944.5K | 260.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,291,115.00 | N/A |
| Revenue This Year | $35.93 | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $2.16 | $5.61 |
Technical Indicators
Market Signals| Indicator | ISPC | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 48.80 |
| Support Level | $0.23 | $0.57 |
| Resistance Level | $0.44 | $1.69 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 12.02 | 83.89 |
Price Performance
Historical ComparisonAbout ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.